Skip to main content
OpenTrials
Completed

NCT Number: NCT02361970

Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism

The purpose of the study is to evaluate the status and function of gamma delta T cells in peripheral blood of sepsis patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

West China Hospital,Sichuan University

Chengdu, Sichuan, 610041, China

About this study

Sepsis therapy is a prominent problem of the modern critical care medicine,and improving the level of sepsis treatment by immune intervention measures is a hot research topic with close attention.Gamma delta T cells is considered as one new T lymphocyte subset in recent years,which playing an important role in resistance to infection,anti-tumor and immune regulating function in the body.First,we played attention to the status and function of gamma delta T cells in peripheral blood of sepsis patients including differentiation marker,subtype and production of related cytokine,and then the molecular mechanism of insufficient gamma delta T cells.At the same time the responsibility of gamma delta T cells of sepsis patients to certain bacteria and viral antigen and the regulation of gamma delta T cells on other natural immune cells including NK cells and mononuclear cells were studied to identify the status and role gamma delta T cells in sepsis immunosuppression by culture in vitro.Further we studied the effect of specific stimulants on proliferation and activation of gamma delta T cells in patients with sepsis and also anti-infection acquired by gamma delta T cells,expecting as an entry point to explore new treatment strategy to sepsis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • clinical symptoms of severe sepsis and septic shock
  • age over 18 years

Exclusion criteria

  • preexisting autoimmune disease
  • patients received immuno-suppressive treatment in the previous 6 months
  • patients with chronic infection,e.g.tuberculosis,hepatitis or HIV infection,etc.
  • pregnancy

Treatment and study plan

Primary outcomes

  1. The percentage of activated gamma delta T cells

    Time frame: within 24h after recruitment

Secondary outcomes

  1. The percentage of apoptotic gamma delta T cells

    Time frame: within 24h after recruitment

Sponsors and collaborators

Lead sponsor

West China Hospital

Other

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Feb 12, 2015
Registry last updated
May 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.